Forskning ved Københavns Universitet - Københavns Universitet

Forside

Biologiske behandlingsmuligheder ved Graves' oftalmopati

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Biologiske behandlingsmuligheder ved Graves' oftalmopati. / El Fassi, Daniel; Nielsen, Claus Henrik; Hegedüs, Laszlo.

I: Ugeskrift for Laeger, Bind 170, Nr. 24, 09.06.2008, s. 2128-30.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

El Fassi, D, Nielsen, CH & Hegedüs, L 2008, 'Biologiske behandlingsmuligheder ved Graves' oftalmopati', Ugeskrift for Laeger, bind 170, nr. 24, s. 2128-30.

APA

El Fassi, D., Nielsen, C. H., & Hegedüs, L. (2008). Biologiske behandlingsmuligheder ved Graves' oftalmopati. Ugeskrift for Laeger, 170(24), 2128-30.

Vancouver

El Fassi D, Nielsen CH, Hegedüs L. Biologiske behandlingsmuligheder ved Graves' oftalmopati. Ugeskrift for Laeger. 2008 jun 9;170(24):2128-30.

Author

El Fassi, Daniel ; Nielsen, Claus Henrik ; Hegedüs, Laszlo. / Biologiske behandlingsmuligheder ved Graves' oftalmopati. I: Ugeskrift for Laeger. 2008 ; Bind 170, Nr. 24. s. 2128-30.

Bibtex

@article{a2cedcaf5934460f8e4e3e4f48b7085a,
title = "Biologiske behandlingsmuligheder ved Graves' oftalmopati",
abstract = "The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO.",
author = "{El Fassi}, Daniel and Nielsen, {Claus Henrik} and Laszlo Heged{\"u}s",
year = "2008",
month = "6",
day = "9",
language = "Dansk",
volume = "170",
pages = "2128--30",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "24",

}

RIS

TY - JOUR

T1 - Biologiske behandlingsmuligheder ved Graves' oftalmopati

AU - El Fassi, Daniel

AU - Nielsen, Claus Henrik

AU - Hegedüs, Laszlo

PY - 2008/6/9

Y1 - 2008/6/9

N2 - The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO.

AB - The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO.

M3 - Tidsskriftartikel

VL - 170

SP - 2128

EP - 2130

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 24

ER -

ID: 34072671